Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Cryo Cell International (CCEL) Long-Term Debt Issuances (2016)

Cryo Cell International's Long-Term Debt Issuances history spans 1 years, with the latest figure at $10.1 million for Q3 2016.

Quarterly results put Long-Term Debt Issuances at $10.1 million for Q3 2016, changed N/A from a year ago — trailing twelve months through Nov 2021 was $10.1 million (changed N/A YoY), and the annual figure for FY2022 was $9.0 million, changed.
Long-Term Debt Issuances for Q3 2016 was $10.1 million at Cryo Cell International.
In the past five years, Long-Term Debt Issuances ranged from a high of $10.1 million in Q3 2016 to a low of $10.1 million in Q3 2016.